Research Article

Inhibition of SphK1/S1P Signaling Pathway Alleviates Fibrosis and Inflammation of Rat Myocardium after Myocardial Infarction

Xiaokui Wu, Junwei Xu, Xiangyu Li, Jian Dai, and Linlin Wang

Department of Cardiology, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing Chest Hospital, Nanjing, China

Correspondence should be addressed to Linlin Wang; wanglinlin2021@njmu.edu.cn

Received 24 May 2022; Revised 17 June 2022; Accepted 18 June 2022; Published 13 July 2022

Academic Editor: Ahmed Faeq Hussein

Copyright © 2022 Xiaokui Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The sphingosine kinase 1 (SphK1)/sphingosine-1-phosphate (S1P) signaling pathway is involved in fibrosis and inflammatory responses of myocardial tissue after myocardial infarction (MI). The purpose of our study was to explore the role of SphK1/S1P signaling pathway in myocardial injury after MI.

Materials and Methods. We used Sprague-Dawley (SD) rats to make MI models and detected the changes of SphK1 and S1P in rats at 1, 7, and 14 days after MI. SphK1 inhibitor PF543 was used to treat MI rats, and we detected the changes in myocardial function and structure in rats by cardiac function test, 2,3,5-triphenyl tetrazolium staining, and histological staining. In addition, we used H2O2 to induce H9c2 cell injury to investigate the effect of PF543 on the viability of myocardial cells.

Results. Myocardial tissue lesions and fibrosis were observed at 7 and 14 days after MI, and the expressions of SphK1 and S1P in the injured myocardial tissues increased significantly in day 7 and day 14 in comparison to the control group. After treatment of MI rats with PF543, the structure of rat myocardial tissue was significantly improved and the degree of fibrosis was reduced. After MI, the expression of α-SMA and collagen I in the myocardium of rats was significantly increased while PF543 decreased their expression. PF543 also improved the cardiac function of MI rats and reduced the expression of IL-1β, IL-6, and TNF-α in the serum. PF543 also increased the viability of H9c2 cells in vitro.

Conclusions. The inhibition of the SphK1/S1P signaling pathway contributed to the relief of myocardial injury in MI rats. PF543 improved the myocardial structure and function of MI rats and reduced the level of fibrosis and inflammation in MI rats.

1. Introduction

Coronary heart disease is a leading cause of death, killing more than 360,000 people every year.

Myocardial infarction (MI) is caused by acute coronary occlusion and leads to myocardial injury in the corresponding blood supply area [1]. Acute MI still frequently leads to heart failure and contributes to cardiovascular morbidity and mortality. Timely restoration of ischemic myocardial blood flow, limitation of infarct size, and improvement of myocardial function have become the standard treatment for MI patients. However, myocardial cells are nonregenerating cells and irreversible injury occurs immediately after 20 minutes of complete ischemia and hypoxia [2]. In addition, during the process of restoring blood supply, the myocardium may also suffer from reperfusion injury, resulting in excessive inflammation and oxidative stress, thereby exacerbating the damage to the myocardial cells [3]. In the repair process after MI, scars formed by fibrous connective tissue without systolic or diastolic function replaced the dead myocardial cells, causing myocardial injury after MI, mainly manifested as cardiac fibrosis and cardiac dysfunction [4]. Therefore, improving myocardial cell viability and reducing the number of dead myocardial cells under ischemic and hypoxic conditions is essential for reducing myocardial injury after MI.

Sphingosine (Sph) kinase 1 (SphK1) and sphingolipid metabolites are important signaling molecules [5]. SphK1 is an enzyme in the sphingomyelin metabolism pathway, which can convert Sph into sphingosine-1-phosphate (S1P)
[6]. SphK1 is widely distributed and expressed at high levels in the brain, heart, lung, and spleen tissues. The SphK1/S1P signaling pathway involves a variety of pathophysiological reactions and participates in the occurrence and development of various diseases such as tumors, autoimmunity, and inflammatory diseases [7]. The absence of SphK1/S1P can reduce the level of endoplasmic reticulum stress in cells [8]. In addition, SphK1/S1P was found to mediate the inhibitory effect of resveratrol on lung tissue remodeling [9]. In cerebral ischemia-reperfusion injury, SphK1/S1P was found to aggravate the injury by inducing endoplasmic reticulum stress and activating the NF-κB signaling pathway [10]. Therefore, in this study, Sprague-Dawley (SD) rats were used to make MI models and were treated with SphK1 inhibitor PF543 to investigate the effect of SphK1/S1P on MI. This is the first study to show that SphK1 and S1P were highly expressed in rat myocardium after MI and investigated the effects of the SphK1/S1P signaling pathway on myocardial fibrosis and inflammation after MI through the use of SphK1 inhibitors. This study will bring up light on the patients with MI and give a reminder novel method to treat this disease.

2. Materials and Methods

2.1. Animals and MI Model. This study was approved by the Animal Ethics Committee of Nanjing Medical University Animal Center. A total of 80 five-to-seven-week-old male SD rats (8 weeks old, 180 ± 20 g) were used in this study. All rats were housed in the Nanjing Medical University Laboratory Animal Center and fed with clean food and water. Before making the MI model, the rat were anesthetized with 2% sodium pentobarbital (40 mg/kg). Then, the rats were placed on the operating table and removed the fur from the rat's chest. A small animal ventilator (CWE SAR-830, Orange, CA, USA) was used to maintain the rat's breathing and set the ventilator's parameters to be the tidal volume of 1 mL, the breathing rate of 110 times/min, and the breathing ratio of 1:1. Then, an electrocardiograph were used to detect the electrocardiogram of the rats. After cutting the skin of the rat's left chest, the rat's ribs were cut and exposed the heart. Then, the pericardium were removed and ligated the left anterior descending coronary artery with a suture. The elevation of the ST segment of the electrocardiogram of the rats. After cutting the skin of the rat's left chest, the rat's ribs were cut and exposed the heart. Then, the pericardium were removed and ligated the left anterior descending coronary artery with a suture. The elevation of the ST segment of the electrocardiogram indicated that myocardial ischemia occurred in the rat. Then, the left chest of the rat were sutured and continued to feed the rat for 1 day, 7 days, and 14 days. The chest cavity of the rats in the sham group were only opened without ligating the coronary arteries. The rats in the MI+PF543 (5 mg/kg) group and MI+PF543 (20 mg/kg) group were treated with PF543 (Selleck, Shanghai, China) daily subcutaneously [11, 12].

2.2. Cardiac Function Test. After ligating the coronary arteries for 1, 7, and 14 days, we performed echocardiography on the four groups of rats to assess their cardiac function of the rats. We used a 15 MHz probe (VisualSonics Vevo 2100, Toronto, Canada) to detect left ventricular ejection fraction (LVEF), left ventricular shortening fraction (LVFS), and early diastolic mitral valve maximum velocity/atrial systole maximum velocity of mitral valve (E/A) ratio based on the results of M-mode ultrasound.

2.3. 2,3,5-Triphenyltetrazolium Chloride (TTC) Staining. We collected rat hearts and placed them in a -20°C refrigerator for 20 minutes. Then, we cut myocardial tissue into slices of 2 mm thickness and soaked them in 1% TTC staining solution (Sigma-Aldrich, St. Louis, MO, USA) for 20 minutes. Infarcted myocardial tissue is pale, and normal myocardial tissue is red.

2.4. Histological Staining. Rat hearts were collected, and myocardial tissue was washed with normal saline. Then, we used 4% pararormaldehyde to fix myocardial tissue. We used gradient alcohol for dehydration and embed myocardial tissue in paraaffin. Then, we used a microtome to make paraffin blocks into paraffin sections. Before hematoxylin-eosin (HE) staining, we put paraffin slices in xylene and gradient alcohol for dewaxing and hydration. Then, we stained the cell nucleus with hematoxylin solution (Beyotime, Shanghai, China) for 1 minute. After rinsing slices with running water, we used 1% hydrochloric acid alcohol for differentiation. Then, we used eosin solution (Beyotime, Shanghai, China) to stain the cytoplasm. Finally, we used neutral gum for sealing. In addition, we used Masson trichrome staining kit (Beyotime, Shanghai, China) for staining according to the manufacturer’s instructions. Collagen fibers appear blue and muscles appear red.

2.5. Immunohistochemical (IHC) Staining. After dewaxing and hydration using xylene and gradient alcohol, we placed the slices in citrate buffer and heated them to 95°C for 20 minutes. Then, we used 3% H2O2 to incubate myocardial tissue for 30 minutes. 10% goat serum was used to block myocardial tissue for 1 hour. Then, we used primary antibody dilution (SphK1, ab61148; S1P, ab224618; α-SMA, ab5694; collagen I, ab34710, Abcam, Cambridge, MA, USA) to incubate myocardial tissue at 4°C overnight. After washing the slices with phosphate buffer solution (PBS), we used secondary antibody dilution (GeneTech, Shanghai, China) to incubate myocardial tissue at room temperature for 1 hour. Then, we used diaminobenzidine (DAB) developer (GeneTech, Shanghai, China) for color development. Finally, we stained the cell nucleus with hematoxylin solution and sealed slices with neutral gum.

2.6. Enzyme-Linked Immunosorbent Assay (ELISA). After collecting the rat serum, we detected the concentration of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor (TNF)-α in the rat serum by ELISA kits (R&D Systems, Emeryville, CA, USA). We added samples and standards to 96-well plates and incubated them with a working solution according to the manufacturer’s instructions. After stopping the reaction with the stop solution, we used a microplate reader ( Molecular Devices, San Jose, CA, USA) to detect the absorbance of each well at 450 nm. Finally, we draw a
standard curve according to the standard and calculated the concentration of the sample.

2.7. Cell Culture. The rat myocardial cell line (H9c2) used in this study was obtained from the National Institutes of Health. We used Dulbecco’s Modified Eagle’s Medium (Gibco, Rockville, MD, USA) containing 10% fetal bovine serum (Gibco, Rockville, MD, USA) and 1% penicillin plus streptomycin (Gibco, Rockville, MD, USA) to culture H9c2 cells. H_{2}O_{2} was used to induce H9c2 cell injury.

2.8. RNA Isolation and Quantitative Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR). We used TRIzol (Invitrogen, Carlsbad, CA, USA) to extract RNA from myocardial tissue and H9c2 cells. A spectrophotometer was used to detect the concentration of RNA. We then used reverse transcription kits (Vazyme, Nanjing, China) to reverse mRNA to complementary deoxyribose nucleic acid (cDNA). We used SYBR Green PCR Master Mix (Vazyme, Nanjing, China) to perform quantitative PCR on cDNA. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal reference to calculate the relative expression of different indicators. 2^{\Delta \Delta Ct} was used to represent the relative expression of different indicators. Primers for RT-PCR was shown in Table 1.

2.9. Cell Counting Kit-8 (CCK8) Assay. We seeded H9c2 cells into 96-well plates and treated them with H_{2}O_{2} and PF543. Then, we added 10 μL of CCK8 reagent (Dojindo Molecular Technologies, Kumamoto, Japan) to each well. After incubating the cells in an incubator for 2 hours, we used a microplate reader to detect the absorbance of each well at 450 nm in the dark.

2.10. Immunofluorescence (IF) Staining. We put cell slides in the 24-well plate and seeded the cells on the slides. After treating the cells, we discarded the medium and washed the cells with PBS. Then, we treated H9c2 cells with 4% paraformaldehyde and 0.01% Triton X-100 in sequence. After blocking the cells with 10% goat serum, primary antibody dilution were used (caspase3, ab13847; caspase9, ab32539, Abcam, Cambridge, MA, USA) to incubate the cells overnight at 4°C. Then, we used secondary antibody dilution (Abcam, Cambridge, MA, USA) to incubate the cells in the dark for 1 hour and stained the cell nucleus with DAPI. Finally, we used a fluorescence microscope to observe the staining results.

2.11. Statistical Analysis. Statistical Product and Service Solutions (SPSS) 21.0 (IBM Corp., Armonk, NY, USA) were used to analyze the data in this study. The mean ± standard deviation was used to represent the measurement data. We analyzed pairwise comparisons by t-test, and we used analysis of variance to analyze differences between multiple groups. p < 0.05 indicated that the difference was statistically significant. All experiments were repeated three times.

### Table 1: RT-PCR primer sequences.

| Name   | Sense/antisense (S/AS) | Sequences (5'→3')          |
|--------|------------------------|----------------------------|
| SphK1  | S                      | TCCACCCGGGAGGAACA          |
|       | AS                     | CCCCTCCAGGCCTCAAC          |
| S1P    | AS                     | AGGCTCTGTTGCTTGTGGT        |
| caspase 3 | S             | TGGACAACAAGAAAACCTC       |
| caspase 9 | AS             | AGCAAGAAGACACTGGGA        |
| Bax    | AS                     | CGGCTGCTTGTGCTGAT         |
| Bcl2   | S                      | GGATGTGAGTAGCACTGGAG       |
| GAPDH  | AS                     | CCCAGGTGCCCTTTAGT         |

3. Results

3.1. SphK1 Was Highly Expressed in Rat Myocardium after MI. At 1 day, 7 days, and 14 days after constructing the MI model, we detected the MI area of rats by TTC staining. The results showed that the MI area of rats was larger than that of the sham group and the MI area of rats was the largest after 14 days of modeling (Figure 1(a)). The results of cardiac function tests showed that after ligating the coronary arteries, the cardiac function of the rats decreased significantly (Figures 1(b)–1(d)). We detected the structural changes of rat myocardium by HE staining (Figure 1(e)) and Masson trichrome staining (Figure 1(f)). Myocardial cells of MI rats were disorderly arranged, and there was a large accumulation of collagen in the interstitium. These results indicated that the MI rat model was successfully established. The results of IHC staining (Figure 1(g)) and RT-PCR (Figures 1(h), and 1(i)) showed that the expressions of SphK1 and S1P were increased in the myocardium of rats after MI.

3.2. PF543 Reduced Myocardial Fibrosis in Rats after MI. The previous results found that at 7 days after MI, the myocardial tissue of the rat has already suffered evident injury and fibrosis, so we chose the 7-day modeling time for follow-up experiments. Considering SphK1 was highly expressed in rat myocardium after MI, we used SphK1 inhibitors to inhibit SphK1 activity and detect changes in rat myocardial structure. The results of HE staining (Figure 2(a)) and Masson trichrome staining (Figure 2(b)) showed that after treatment with PF543, the structure of rat myocardial tissue was significantly improved and collagen was reduced. IHC staining detected the expression of α-smooth muscle actin (α-SMA) and collagen I. After MI, the expression of α-SMA and collagen I in the myocardium of rats was significantly increased while PF543 decreased their expression (Figure 2(c)).

3.3. PF543 Improved Cardiac Function and Inhibited Inflammation in Rats after MI. We detected the changes in
Figure 1: SphK1 was highly expressed in rat myocardium after MI. (a) Myocardial ischemic area of rats was increased from 1 to 14 days. (b–d) LVEF, LVFS, and E/A of rats decreased from 1 to 14 days. (e, f) HE staining and Masson trichrome staining of rat myocardium (200x). (g) IHC staining results showed that the expression of SphK1 and S1P in rat myocardium (200x) increased from 1 to 14 days. (h, i) mRNA expression of SphK1 and S1P in rat myocardium increased from 1 to 14 days. (⁎⁎ means p < 0.05 vs. the sham group), based on Student’s t-test. Scale bar: 50 μm.
inflammatory factors in rat serum by ELISA (Figure 3(a)). The expression of IL-1β, IL-6, and TNF-α in the serum of MI rats increased significantly, while PF543 inhibitor of Sphk1 reduced the expression of these inflammatory factors and a high concentration of PF543 had better effects. RT-PCR results also found that PF543 can reduce the RNA levels of these inflammatory factors, IL-1β, IL-6, and TNF-α (Figure 3(b)). The results of TTC staining showed that PF543 can reduce the MI area (Figure 3(c)). The results of cardiac function tests showed that PF543 improved the cardiac function of rats, which was manifested by the increase of LVEF (Figure 3(d)), LVFS (Figure 3(e)), and E/A (Figure 3(f)).

3.4. PF543 Improved the Viability of H9c2 Cells and Inhibited Their Apoptosis. To determine the role of SphK1 in myocardial cells, we used SphK1 inhibitor PF543 to stimulate H9c2 cells. We detected the effect of different concentrations of H$_2$O$_2$ and PF543 on the proliferation ability of H9c2 cells through the CCK8 assay. 500, 700, and 1000 μM of H$_2$O$_2$ were found to significantly reduce the proliferation ability of H$_2$O$_2$ cells, so we used 700 μM H$_2$O$_2$ to induce H9c2 cell injury (Figure 4(a)). In H9c2 cells treated with PF543, the best results were obtained with 10 μM PF543 (Figure 4(b)). In addition, stimulation of PF543 improved H$_2$O$_2$-induced cell injury (Figure 4(c)). IF staining detected the expression of apoptosis-related molecule caspase3/9. The expression of caspase3/9 in H9c2 cells induced by H$_2$O$_2$ was significantly higher than that in the control group, while the stimulation of PF543 reduced the expression of caspase3/9 (Figures 4(d) and 4(e)). RT-PCR results also showed that inhibition of SphK1 can reduce the expression of caspase3/9 and Bax in H9c2 cells and can increase the expression of anti-apoptotic molecule Bcl2 (Figure 4(f)).

4. Discussion

MI is one of the primary causes of human death and the pathophysiological mechanism of myocardial injury after MI has been a hot research topic in the field of cardiovascular disease [1]. Several pathophysiological mechanisms explain the occurrence and development of myocardial injury after myocardial infarction. Braunersreuther et al. [13] demonstrated the role of oxidative stress in promoting myocardial injury after MI using a mouse model of myocardial injury. Zhou et al. [14] found excessive inflammation in

![Image](image_url)
Figure 3: Continued.
patients after MI in many clinical studies. Khalilzadeh et al. [15] also explained the progression of myocardial injury after MI in a rat model with cell calcium overload. This study found that the expressions of SphK1 and S1P in the myocardium of rats after MI increased significantly with the time of MI, indicating that SphK1/S1P was involved in the disease process of MI. After treating MI rats with PF543, the myocardial structure of the rats was significantly improved and the degree of fibrosis was reduced. The inflammation level of MI rats also decreased with the treatment of PF543. In addition, PF543 was also found to promote the proliferation of H9c2 cells in vitro and reduce H₂O₂-induced apoptosis. Therefore, SphK1/S1P may be a potential therapeutic target for MI.

Myocardial fibrosis is an important cause of long-term poor prognosis in MI patients and compensatory response to myocardial injury [2]. The occurrence and development of many cardiovascular diseases are related to myocardial fibrosis, which is characterized by the accumulation of activated cardiac fibroblasts (myofibroblasts) and excessive deposition of extracellular matrix [16, 17]. Myofibroblasts are fibroblast-like cells that can express α-SMA. They have both the contraction function of smooth muscle cells and the function of fibroblasts to secrete extracellular matrix [18]. Unbalanced collagen ratio, disordered arrangement, or abnormal concentration will promote myocardial fibrosis, increase the stiffness of the ventricular wall, and reduce the compliance of the ventricular wall, resulting in the weakening of myocardial diastolic function and cardiac diastolic dysfunction [19]. The SphK1/S1P signaling pathway has been studied in detail in fibrotic diseases. Xiu et al. [20] found that stimulation of bleomycin or TGF-β can lead to increased levels of SphK1 and S1P in lung tissue and human embryonic lung fibroblasts (HELF), respectively. Sferra et al. [21] also found in bleomycin-induced lung fibrosis model mice that the expression of SphK1 mRNA and protein in the lung tissue of mice increased. After the SphK inhibitor was used, the degree of bleomycin-induced lung injury and fibrosis was significantly reduced. At the same time, in HELF stimulated by bleomycin or TGF-β, the expression of SphK1 mRNA and protein increased, and the expression of fibrosis phenotype-related markers fibronectin and α-SMA also increased. Bleomycin-induced lung injury and fibrosis were significantly reduced when SphK inhibitor was used. These results indicated that the pulmonary fibrosis process mediated by TGF-β may rely on SphK1 as the rate-limiting enzyme for the synthesis of S1P. In addition, the intracellular SphK1/S1P signal was also found to result in increased collagen expression of fibroblasts in the liver [22]. Therefore, we investigated the effect of SphK1/S1P signaling pathway on myocardial fibrosis in MI. The results of Masson trichrome staining and IHC staining showed that myocardial tissues of rats had obvious fibrosis at 7 and 14 days after MI, while the treatment of PF543 (inhibitor of Sphk1) reduced the degree of myocardial fibrosis.

SphK1 and S1P are an important class of signaling molecules with important biological activities. They are involved in the regulation of cell growth, differentiation, senescence, and death [23]. After S1P acts on the S1P receptor (S1PR), it can play an important regulatory role in many physiological and biochemical processes. In myocardial tissue, S1P can regulate cardiac electrophysiology and contractile activity, and S1PR1 can inhibit cAMP-mediated L-type calcium ion channels in myocardial cells, reducing myocardial contractility [24]. G protein-gated inward rectifier potassium channels in myocardial cells can be activated by S1PR3, reducing myocardial contractility [25]. In this study, the use of SphK1 inhibitors effectively increased the LVEF, LVFS, and E/A of MI rats, so inhibition of SphK1/S1P may become one of
Figure 4: Continued.
the methods to improve the cardiac function of MI rats. In addition, some studies have shown that when inflammation occurs in the body, the expression of SphK1/S1P signaling pathway in cells at the site of inflammation is significantly increased [26, 27]. SphK1 and S1P were found to be significantly increased in the spinal cord of patients with multiple sclerosis and the serum and cerebrospinal fluid of mice with autoimmune encephalomyelitis [28]. These indicated that the SphK1/S1P signaling pathway may be involved in the progression of inflammatory diseases [29, 30]. We found that the expression of inflammatory factors in MI rats increased significantly, and PF543 showed a good anti-inflammatory effect.

To our knowledge, this is the first study to investigate the effect of the SphK1/S1P signaling pathway on MI and previous studies did not report. Our results suggested that SphK1/S1P inhibitor has a good application prospect for MI. However, this study did not contain the clinical tissues in patients, which lack the verification of the results. Besides, the underlying mechanism of this study is not clarified, which needs further studies to verify it. Next, we can focus on how the SphK1/S1P relieve MI and which molecule plays a main role in the progress.

5. Conclusions
To sum up, this is the first study to show that SphK1 and S1P were highly expressed in the rat myocardium after MI and investigated the effects of the SphK1/S1P signaling
pathway on myocardial fibrosis and inflammation after MI through the use of SphK1 inhibitors. The SphK1/S1P signaling pathway may become a new target for clinical treatment of MI.

Data Availability
The data could be obtained from contacting the corresponding author.

Conflicts of Interest
The authors declared no conflict of interest.

Acknowledgments
This study was supported by the Natural Science Fund of Jiangsu Province (BK20160134).

References
[1] A. R. Choi, M. H. Jeong, Y. J. Hong et al., “Clinical characteristics and outcomes in acute myocardial infarction patients with versus without any cardiovascular risk factors,” The Korean Journal of Internal Medicine, vol. 34, no. 5, pp. 1040–1049, 2019.
[2] M. DeBerge, S. Yu, S. Dehn et al., “Monocytes prime autoreactive T cells after myocardial infarction,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 318, no. 1, pp. H116–H123, 2020.
[3] M. Boulanger, L. Li, S. Lyons et al., “Essen risk score in prediction of myocardial infarction after transient ischemic attack or ischemic stroke without prior coronary artery disease,” Stroke, vol. 50, no. 12, pp. 3393–3399, 2019.
[4] P. Vejpongsa, D. Kittkungvan, M. Madjid et al., “Outcomes of acute myocardial infarction in patients with influenza and other viral respiratory infections,” The American Journal of Medicine, vol. 132, no. 10, pp. 1173–1181, 2019.
[5] S. Mohammed, N. S. Vineetha, S. James et al., “Regulatory role of SphK1 in TLR7/9-dependent type I interferon response and autoimmunity,” The FASEB Journal, vol. 34, no. 3, pp. 4329–4347, 2020.
[6] P. C. Hart, T. Chiyoda, X. Liu et al., “SphK1 is a novel target of metformin in ovarian cancer,” Molecular Cancer Research, vol. 17, no. 4, pp. 870–881, 2019.
[7] S. Yin, Z. Miao, Y. Tan et al., “SphK1-induced autophagy in peritoneal mesothelial cell enhances gastric cancer peritoneal dissemination,” Cancer Medicine, vol. 8, no. 4, pp. 1731–1743, 2019.
[8] L. Li, H. Wang, J. Zhang et al., “SphK1 deficiency protects mice from acetaminophen-induced ER stress and mitochondrial permeability transition,” Cell Death and Differentiation, vol. 27, no. 6, pp. 1924–1937, 2020.
[9] W. Shi, C. Zhai, W. Feng et al., “Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of Sphk1-mediated NF-xB activation,” Life Sciences, vol. 210, pp. 140–149, 2018.
[10] M. Zhang, D. Zhou, Z. Ouyang, M. Yu, and Y. Jiang, “Sphingosine kinase 1 promotes cerebral ischemia-reperfusion injury through inducing ER stress and activating the NF-xB signaling pathway,” Journal of Cellular Physiology, vol. 235, no. 10, pp. 6605–6614, 2020.
[11] E. Jozefczuk, R. Nosalski, B. Saju et al., “Cardiovascular effects of pharmacological targeting of sphingosine kinase 1,” Hypertension, vol. 75, no. 2, pp. 383–392, 2020.
[12] M. Sun, Y. Zhou, Y. Shi, and B. Liu, “Effect of the sphingosine kinase 1 selective inhibitor, PF543 on dextran sodium sulfate-induced colitis in mice,” DNA and Cell Biology, vol. 38, no. 11, pp. 1338–1345, 2019.
[13] V. Brauersreuther, F. Montecucco, M. Asrith et al., “Role of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in myocardial ischemia/reperfusion injury,” Journal of Molecular and Cellular Cardiology, vol. 64, pp. 99–107, 2013.
[14] X. Zhou, J. Li, J. Guo et al., “Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction,” Microbiome, vol. 6, no. 1, p. 66, 2018.
[15] M. Khalilzadeh, A. Abdollahi, F. Abdolahifar, A. R. Dehpour, and F. Jazaeri, “Protective effects of magnesium sulfate against doxorubicin induced cardiotoxicity in rats,” Life Sciences, vol. 207, pp. 436–441, 2018.
[16] N. Kawel-Boehm, R. L. McClelland, F. Zemrak et al., “Hypertrabeculated left ventricular myocardium in relationship to myocardial function and fibrosis: the multi-ethnic study of atherosclerosis,” Radiology, vol. 284, no. 3, pp. 667–675, 2017.
[17] I. Abe, Y. Teshima, H. Kondo et al., “Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation,” Heart Rhythm, vol. 15, no. 11, pp. 1717–1727, 2018.
[18] K. A. Duggan, G. Hodge, J. Chen, and T. Hunter, “Vasoactive intestinal peptide infusion reverses existing myocardial fibrosis in the rat,” European Journal of Pharmacology, vol. 862, p. 172629, 2019.
[19] S. K. Hong, E. H. Choo, S. H. Ihm, K. Chang, and K. B. Seung, “Dipeptidyl peptidase 4 inhibitor attenuates obesity-induced myocardial fibrosis by inhibiting transforming growth factor-β and Smad2/3 pathways in high-fat diet-induced obesity rat model,” Metabolism, vol. 76, pp. 42–55, 2017.
[20] L. Xiu, N. Chang, L. Yang et al., “Intracellular sphingosine 1-phosphate contributes to collagen expression of hepatic myofibroblasts in human liver fibrosis independent of its receptors,” The American Journal of Pathology, vol. 185, no. 2, pp. 387–398, 2015.
[21] R. Sierra, S. Pompili, L. Ventura et al., “Interaction between sphingosine kinase/sphingosine 1 phosphate and transforming growth factor-beta/Smads pathways in experimental intestinal fibrosis. An in vivo immunohistochemical study,” European Journal of Histochemistry, vol. 62, p. 2956, 2018.
[22] T. Lan, C. Li, G. Yang et al., “Sphingosine kinase 1 promotes liver fibrosis by preventing miR-19b-3p-mediated inhibition of CCR2,” Hepatology, vol. 68, no. 3, pp. 1070–1086, 2018.
[23] Z. Gao, H. Wang, F. J. Xiao et al., “SIRT1 mediates Sphk1/S1P-induced proliferation and migration of endothelial cells,” The International Journal of Biochemistry & Cell Biology, vol. 74, pp. 152–160, 2016.
[24] D. K. Lee, Y. S. Min, S. S. Yoo, H. S. Shim, S. Y. Park, and U. D. Sohn, “Effect of Sphingosine-1-phosphate on intracellular free Ca2+ in cat esophageal smooth muscle cells,” Biomolecules & Therapeutics, vol. 26, no. 6, pp. 546–552, 2018.
A. Vestri, F. Pierucci, A. Frati, L. Monaco, and E. Meacci, "Sphingosine 1-phosphate receptors: do they have a therapeutic potential in cardiac fibrosis?,” *Frontiers in Pharmacology*, vol. 8, p. 296, 2017.

Z. Zheng, Y. Z. Zeng, K. Ren et al., "S1P promotes inflammation-induced tube formation by HLECs via the S1PR1/NF-κB pathway,” *International Immunopharmacology*, vol. 66, pp. 224–235, 2019.

M. Nagahashi, A. Yamada, E. Katsuta et al., "Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation, and breast cancer metastasis,” *Cancer Research*, vol. 78, no. 7, pp. 1713–1725, 2018.

A. Musella, A. Gentile, L. Guadalupi et al., "Central modulation of selective sphingosine-1-phosphate receptor 1 ameliorates experimental multiple sclerosis,” *Cells*, vol. 9, no. 5, p. 1290, 2020.

R. Wang, W. Yonggang, and S. Jiang, "FOXC2 alleviates myocardial ischemia-reperfusion injury in rats through regulating Nrf2/HO-1 signaling pathway,” *Disease Markers*, vol. 2021, Article ID 9628521, 9 pages, 2021.

Y. Li, Z. Li, J. Liu, Y. Liu, and G. Miao, "miR-190-5p alleviates myocardial ischemia-reperfusion injury by targeting PHLPP1,” *Disease Markers*, vol. 2021, Article ID 8709298, 11 pages, 2021.